3 results
Primary:• To prove the superiority of a 12-week add-on treatment with 3.2 g/daygastro-resistant phosphatidylcholine granules (LT-02) in at least one of twodifferent dosing regimens versus LT-02 placebo for the induction ofremission in patients with…
To evaluate the safety and effectiveness of the OMGEA Coronary Stent System for the treatment of subjects with a de novo atherosclerotic coronary artery lesion * 28 mm in length (by visual estimate) in a native coronary artery *2.25 mm to *4.50 mm…
Primary objective: To assess the PK of oral FT011 in participants with diffuse SSc.Secondary objectives: • To assess the safety and tolerability of oral FT011 compared to placebo in participants with diffuse SSc.• To evaluate the short-term efficacy…